EUCTR2020-002826-97-IT进行中（未招募）1 期
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCRPHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe RenalImpairment, With or Without Dialysis - PHYOX 7: Safety & Efficacy of DCR-PHXC in patients with PH1/2 and ESRD
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- •1. Four age groups of participants will be enrolled, in sequence:
- •a. adults and adolescents (aged = 12 years; 6 participants)
- •b. children 6 to 11 years of age (2 participants)
- •c. children 2 to 5 years of age (2 participants) and
- •d. infants and newborns from birth to < 2 years of age (2 participants).
- •Type of Participant and Disease Characteristics
- •2. Documented diagnosis of PH1 or PH2, confirmed by genotyping (historically available genotype information is acceptable for study eligibility)
- •3. Estimated GFR at Screening < 30 mL/min normalized to 1.73 m2 BSA.
- •See Section 8.2.6.2 for equations. For infants aged less than 12 months, serum creatinine above the 97th percentile of a healthy population (Boer et al., 2010)
- •4. Mean of 3 plasma oxalate values > 30 µmol/L during Screening
- •5. Less than 20% variation from the median Screening period Pox value
- •6. For participants receiving hemodialysis or peritoneal dialysis, total duration of hemodialysis or peritoneal dialysis must be less than or equal to 18 months and hemodialysis or peritoneal dialysis regimen must have been stable for at least 3 months prior to Screening.
- •7. Body weight of:
- •a. adults and adolescents aged = 12 years: = 31.0 kg
- •b. children 6 to 11 years of age: to be determined
- •c. children 2 to 5 years of age: to be determined
- •d. infants and newborns from birth to < 2 years of age: to be determined
- •8. Male or female
- •Male participants:
- •A male participant with a female partner of childbearing potential must agree to use contraception, as detailed in Section 10.4.2, during the treatment period and for at least 12 weeks after the last dose of study intervention and refrain from donating sperm during this period.
- •Female participants:
- •A female participant is eligible to participate if she is not pregnant (see Section 10.4.3), not breastfeeding, and at least one of the following conditions applies:
- •Not a woman of childbearing potential (WOCBP) as defined in Section 10.4.1.1.
- •A WOCBP who agrees to follow the contraceptive guidance in Section 10.4.2.2 for the 4 weeks prior to randomization, during the treatment period, and for at least 12 weeks after the last dose of study intervention and agrees to refrain from harvesting/freezing eggs during this period.
- •Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- •Informed Consent/Assent
- •9. Participant (and/or participant's parent or legal guardian if participant is a minor [defined as patient < 18 years of age, or younger than the age of majority according to local regulations]) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •a. Adolescents (12 to < 18 years of age, or older than 12 years but younger than the age of majority according to local regulations) must be able to provide written assent for participation.
- •b. For children younger than 12 years of age, assent will be based on local regulations.
- •10. Affiliated with or is a beneficiary of a health insurance system (if applicable per national regulations)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 6
- •F.1.3 Elderly (>=65
排除标准
- •An individual who meets any of the following criteria will be excluded from participation in this study:
- •Medical Conditions
- •1. Prior hepatic transplantation; or scheduled transplantation within 6 months of Day 1. Prior renal transplantation is allowed.
- •2. Known history of severe systemic oxalosis
- •3. Presence of any condition or comorbidities that would interfere with study compliance or data interpretation or potentially impact patient
- •safety including, but not restricted to:
- •a. Severe intercurrent illness
- •b. Known causes of active liver disease/injury (e.g., alcoholic liver disease, nonalcoholic fatty liver disease/steatohepatitis)
- •c. Physician concerns about intake of drugs of abuse or excessive alcohol intake, or history of excessive alcohol intake in the 2 years prior to
- •enrollment (defined as = 21 units of alcohol per week in men and = 14 units of alcohol per week in women; where a unit of alcohol is equivalent to a 12-ounce beer, 4-ounce glass of wine, or 1 ounce shot of hard liquor)
- •Prior/Concomitant Therapy
- •4. Use of an RNAi drug, other than DCR-PHXC, within the last 6 months
- •5. History of one or more of the following reactions to an oligonucleotide-based therapy:
- •a. Severe thrombocytopenia (platelet count = 100,000/µL)
- •b. Hepatotoxicity, defined as alanine transaminase (ALT) or aspartate transaminase (AST) > 3 times the upper limit of normal (ULN) and total
- •bilirubin > 2 × ULN or international normalized ratio (INR) >1.5
- •c. Severe flu-like symptoms leading to discontinuation of therapy
- •d. Localized skin reaction from the injection (graded severe) leading to
- •discontinuation of therapy
- •e. Coagulopathy/clinically significant prolongation of clotting time
- •Prior/Concurrent Clinical Study Experience
- •6. Participation in any clinical study in which they received an investigational medicinal product (IMP) other than DCR-PHXC within 4 months or 5 times the half-life of the drug (whichever is longer) before Screening.
- •Diagnostic Assessments
- •7. Liver function test abnormalities: ALT and/or AST >1.5 × ULN for age and gender
- •8. Positive anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibody test at Screening
- •Other Exclusions
- •9. Known hypersensitivity to DCR-PHXC or any of its ingredients
- •10. Inability or unwillingness to comply with the specified study procedures, including the lifestyle considerations detailed in Section 5.3.
研究者
相似试验
尚未招募
2 期
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without DialysisPrimary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)Kidney DiseasesUrologic DiseasesGenetic DiseaseT51.2LBCTR2022125202Dicerna Pharmaceuticals30
进行中（未招募）
1 期
Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXCEUCTR2020-002826-97-FRDicerna Pharmaceuticals Inc24
进行中（未招募）
1 期
Study for patients with Primary Hyperoxaluria and Severe Renal Impairment to evaluate the efficacy, safety and tolerability of DCR-PHXCEUCTR2020-002826-97-DEDicerna Pharmaceuticals Inc. (a Novo Nordisk Company)28
进行中（未招募）
1 期
Study to evaluate the safety and efficacy of APX001 in the treatment of patients with invasive mold infectionsEUCTR2019-001386-33-BEAmplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer, Inc.50
进行中（未招募）
1 期
Study to test CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast CancerHR-positive/HER2-negative breast cancerTriple-negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2020-004618-36-ESCytomX Therapeutics, Inc.150